reference/27069172

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27069172

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	961
issn	0741-238X 1865-8652
issueIdentifier	4
pageRange	950-961
publicationName	Advances in Therapy
startingPage	950
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c142e310cf1889900ac13cc74784585c
bibliographicCitation	Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S. Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia. Advances in Therapy. 2019 Feb 13;36(4):950–61. doi: 10.1007/s12325-019-0873-7.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c3db502a98cc3bbba3bedc8b2e0ab903 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f99e7aa7a1e7f44b8ae93a1a7328fc6b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6d95c75840bd833a14de984cb184b15a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_46d3057246ae40dddd408c3ebd11162b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf8199a620f65e774749308944a51947 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fcbad4edf3e74d05c7c538df053b4a5f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb530bad5ad88764ee0c10914aa739ce http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c2191e3928b88e49c33dc77ab7035f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1632e02ac14bfdd01a8a7688c197d1ac
date	2019-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/30758745 https://pubmed.ncbi.nlm.nih.gov/PMC6824351 https://doi.org/10.1007/s12325-019-0873-7
isPartOf	https://portal.issn.org/resource/ISSN/0741-238X http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2011 https://portal.issn.org/resource/ISSN/1865-8652
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/ https://scigraph.springernature.com/
title	Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
discusses	http://id.nlm.nih.gov/mesh/M0027219 http://id.nlm.nih.gov/mesh/M0498704 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M000626416 http://id.nlm.nih.gov/mesh/M0482497
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11043 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9942071

Total number of triples: 38.